Treatment and diagnosis of autoantibody-mediated eye diseases

摘要

The present disclosure includes one or more pharmaceutically acceptable excipients; providing an ophthalmic formulation comprising a pharmaceutically active compound, such as an IgG, capable of reducing the amount or deleterious action of an autoantibody on the ocular surface; In particular, the present disclosure relates to inflammatory, infectious and immunological ocular surface or intraocular diseases in which pharmaceutically active compounds may cause symptoms of eye discomfort, keratitis, dry eye syndrome, glomerulonephritis, shortening of the meninges, eyelid margin/conjunctival sac keratosis, Provided is an ophthalmic formulation capable of treating a clinical disease selected from the group consisting of subconjunctival fibrosis, grand retinopathy and glaucoma.